On May 8, 2025, MetaVia Inc. completed a private placement agreement raising approximately $10 million by issuing 9,479,345 shares at $0.71 each and 4,605,162 pre-funded warrants for $0.709 each to accredited investors, aimed to support the clinical development of DA-1726 for obesity treatment.